Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Toprol-XL patents found invalid

Executive Summary

The U.S. Court of Appeals for the Federal Circuit upheld a district court ruling that AstraZeneca's Toprol-XL (metoprolol succinate) patents are invalid and unenforceable based on double patenting. However, the court vacated the lower court's finding of inequitable conduct by AstraZeneca. The court concluded that there are questions of fact involving AstraZeneca's failure to disclose a dispute over inventorship to the U.S. Patent and Trademark Office and sent the issue back to the U.S. District Court for the Eastern District of Missouri for review. AstraZeneca filed suit against KV Pharmaceutical, Andrx and Eon Labs after they filed ANDAs to market generic versions of the hypertension treatment. Sandoz and KV subsequently filed citizen petitions to block each other from marketing formulations of the drug (1"The Pink Sheet" July 9, 2007, p. 26)...
Advertisement

Related Content

Generic Firms Use Pediatric Exclusivity As Weapon In Toprol XL Fight
Generic Firms Use Pediatric Exclusivity As Weapon In Toprol XL Fight
Advertisement
UsernamePublicRestriction

Register

PS048631

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel